SUPPLEMENTARY FIGURES



Supplementary Figure 1. Progression-free survival (PFS) of patients with urinary cancer (**A**) and other cancers (**B**).



Variables	Disitamab Vedotin+ICIs	Disitamab Vedotin alone	P value	HR (95% CI)
All patients	34	15	0.45	1.39 (0.58-3.34)
Age				
<60	17	8	0.24	2.06 (0.63-6.78)
>=60	17	7	0.49	1.96 (0.31-12.57)
Sex				
Male	18	4	0.58	0.60 (0.07-4.76)
Female	16	11	0.91	0.91 (0.32-2.57)
Pathology				
Urothelial Carcinoma	18	7	0.44	1.84 (0.39-8.78)
Adenocarcinoma	10	2	0.31	0.31 (0.03-3.01)
Others	6	6	0.17	0.22 (0.02-1.92)
Metastasis				
Yes	6	5	0.78	1.42 (0.13-15.89)
No	28	10	0.74	0.74 (0.28-1.96)
Prior surgery				
No	12	2	0.78	1.37 (0.16-11.51)
Yes	22	13	0.2	2.04 (0.68-6.07)
Prior chemotherapy				
No	19	5	0.76	0.72 (0.09-5.98)
Yes	15	10	0.71	1.21 (0.44-3.36)
Prior radiotherapy				
No	25	10	0.51	1.44 (0.49-4.23)
Yes	9	5	0.96	0.96 (0.19-4.74)
Number of prior treatment lines				
0	12	5	0.95	1.06 (0.10-11.76)
1	9	1	0.96	2.47 (0.82-7.43)
>=2	23	9	0.5	0.50 (0.07-3.62)
Dosage of Disitamab Vedotin				
120mg, d1, q2w	28	12	0.43	1.24 (0.46-3.33)
Others	6	3	0.67	2.21 (0.31-15.82)
Number of treatment cycles				
1-3	15	6	0.86	0.88 (0.23-3.35)
4-8	16	5	0.41	2.04 (0.37-11.22)
>=8	3	4	0.39	60.22 (0.01-668175.28)

Supplementary Figure 2. Stratified survival analyses of the Disitamab Vedotin combined with ICIs and Disitamab Vedotin cohorts (progression-free survival).



Supplementary Figure 3. Multivariate analysis of the associations between progression-free survival and clinicodemographic variables.